Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers

AAPS PharmSci

Volumn 4, Issue 4, 2002, Pages

  Iyer, Ganesh R ^a,b   Liao, Sam ^a,c   Massarella, Joseph ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PharmMax Research   (United States)

Author keywords

Influenza virus; Pharmacokinetics and pharmacodynamics; Population; RWJ 270201

Indexed keywords

CELL SURFACE PROTEIN; GLYCOLIPID; PERAMIVIR; PLACEBO; SIALIC ACID; SIALIDASE INHIBITOR; VIRUS SIALIDASE; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; SIALIDASE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MALE; NORMAL HUMAN; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT MUCOSA; REVIEW; TIME; VIROGENESIS; VIRUS INHIBITION; VIRUS TRANSMISSION; VOLUNTEER; ARTICLE; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY; VIRUS LOAD;

ADULT; CYCLOPENTANES; DOUBLE-BLIND METHOD; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; VIRAL LOAD;

EID: 85046915106     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps040422     Document Type: Review

References (12)

1. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. The Lancet. 2000;355:827-835.
2. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs. 1998;56:537-553.
3. Kim CU, Chen X, Mendel DB. Neuraminidase inhibitors as anti influenza virus agents. Antiviral Chem Chemother. 1999;10:141-154.
4. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker; 1982:31-56.
5. Holford NHG, Sheiner LB. Understanding the dose-effect relationship. Clinical applications of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6:429-453.
6. WinNonMix User's Guide. Pharsight Corp. Version 2.0; 2000.
7. Ette EI, Ludden TM. Population pharmaokinetic model building: The use of informative graphics. Pharm Res. 1995;12:1845-1855.
8. Food and Drug Administration. FDA Guidance for Industry: Population Pharmacokinetics. Rockville, MD: National Press Office; February 1999.
9. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
10. Drusano GL. Pharmacodynamics of antiretroviral chemotherapy. Infec Control Hosp Epidemiol. 1993;14:530-536.
11. Weller S, Radomski KM, Lou Y, Stein DS. Population pharmacokinetics and pharmacodynamic modeling of Abacavir from a dose ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemothera. 2000;44:2052-2060.
12. Smith PF, Puchalski TT, Forrest A. Optimal design of Phase II antiretoviral, short-term monotherapy clinical trials. Poster # 1653. Presented at: ICAAC Meeting; September 2000; Toronto, Canada.